<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141865</url>
  </required_header>
  <id_info>
    <org_study_id>2019-006</org_study_id>
    <nct_id>NCT04141865</nct_id>
  </id_info>
  <brief_title>Effect of Xen Implantation on the Aqueous Humor Proteome</brief_title>
  <official_title>Effect of Xen Implantation on the Aqueous Humor Proteome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how the aqueous humor proteome changes after
      implantation of a Xen microstent for treatment of glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine how the aqueous humor proteome changes after
      implantation of a Xen microstent for treatment of glaucoma using liquid chromatography mass
      spectrometry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous humor proteome</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>The aqueous humor proteome will be assessed with liquid chromotography/mass spectometry (quantitative LC-MS/MS).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Xen</arm_group_label>
    <description>Patients treated with a Xen microstent for glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aqueous shunt</arm_group_label>
    <description>Patients treated with an aqueous shunt for glaucoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xen</intervention_name>
    <description>Xen microstent implantation</description>
    <arm_group_label>Xen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aqueous shunt</intervention_name>
    <description>Aqueous shunt implantation</description>
    <arm_group_label>Aqueous shunt</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aqueous humor
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with open angle glaucoma treated with a glaucoma drainage device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of any racial or ethnic origin, 18 years or older

          -  Able to provide written informed consent.

          -  Scheduled to undergo Xen implantation for open angle glaucoma or already has an
             aqueous shunt

        Exclusion Criteria:

          -  History of conjunctivitis or any ocular infection within the past 3 weeks.

          -  Any active inflammation of the cornea or the anterior chamber (uveitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Price, PhD</last_name>
    <phone>317-814-2990</phone>
    <email>mprice@cornea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Price, PhD</last_name>
      <phone>317-814-2990</phone>
      <email>mprice@cornea.org</email>
    </contact>
    <investigator>
      <last_name>Francis Price, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Feng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>de-identified data will be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

